GO:0001596 angiotensin type I receptor activity: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0001596 (angiotensin type I receptor activity) is a molecular function defined as an angiotensin receptor activity that acts via Gq-mediated activation of phospholipase C followed by phosphoinositide hydrolysis and Ca2+ signaling, and may act via additional signaling mechanisms [1,2].
• The angiotensin II type 1 receptor (AGTR1) is the prototypical protein carrying this activity and is a central effector of the classical renin-angiotensin system [2,3].
• AGTR1 signaling is not limited to Gq/PLC/Ca2+; it also engages Jak2-Stat1/Stat3 and other pathways, a phenomenon known as functional selectivity or biased agonism [7,8].
• Agonist residence time at AGTR1 determines tachyphylaxis, linking receptor kinetics to physiological responsiveness.
• The counter-regulatory arm of the renin-angiotensin system, including AGTR2 and alternative RAS peptides, modulates the effects of AGTR1 and is a major research focus [2,5,6].
• AGTR1 is a validated drug target in hypertension, chronic kidney disease, and cardiovascular disease, and is studied using CRISPR knockout, point-mutation, knock-in, and overexpression models [1,3,4].
Description
Angiotensin type I receptor activity (GO:0001596) is a molecular function that mediates cellular responses to angiotensin II, the principal effector peptide of the renin-angiotensin system [2,3]. The term describes an angiotensin receptor activity that acts via Gq-mediated activation of phospholipase C followed by phosphoinositide hydrolysis and Ca2+ signaling, and may act via additional signaling mechanisms [1,2]. This activity is essential for blood pressure regulation, fluid homeostasis, and cardiovascular remodeling, and its dysregulation contributes to hypertension, chronic kidney disease, and heart failure [1,3]. Researchers study GO:0001596 to understand how angiotensin II type 1 receptor (AGTR1) signaling is initiated, how it is biased toward different downstream pathways, and how it can be selectively modulated for therapeutic benefit [4,8]. The availability of CRISPR-based cell models now allows precise interrogation of AGTR1 function and its signaling partners in physiologically relevant contexts [3,4].
angiotensin type I receptor activity At A Glance
| GO ID | GO:0001596 |
|---|---|
| GO term | angiotensin type I receptor activity |
| Ontology | molecular_function |
| Synonym | PLC-activating angiotensin receptor activity |
| Major function | Gq-mediated activation of phospholipase C, phosphoinositide hydrolysis, and Ca2+ signaling in response to angiotensin II [1,2] |
| Additional signaling | May act via additional mechanisms including Jak2-Stat1/Stat3 activation [7,8] |
| Prototypical protein | Angiotensin II type 1 receptor (AGTR1) [2,3] |
| Related receptor | Angiotensin II type 2 receptor (AGTR2) couples to Gi and counter-regulates AGTR1 [5,6] |
| Agonist kinetics | Agonist residence time defines tachyphylaxis at AGTR1 |
What Is GO:0001596?
GO:0001596, angiotensin type I receptor activity, is defined as an angiotensin receptor activity that acts via Gq-mediated activation of phospholipase C followed by phosphoinositide hydrolysis and Ca2+ signaling, and may act via additional signaling mechanisms [1,2]. In other words, it is the receptor function that binds angiotensin II and couples to Gq proteins to trigger phospholipase C, generating inositol trisphosphate and diacylglycerol, which mobilize intracellular calcium and activate protein kinase C [2,8]. The definition also acknowledges that this activity can signal through other pathways, such as Jak2-Stat1/Stat3, reflecting the functional selectivity of the receptor [7,8].
Why Is angiotensin type I receptor activity Important in Cell Biology?
GO:0001596 is important because it represents the primary molecular function through which angiotensin II exerts its classical physiological and pathophysiological effects, including vasoconstriction, aldosterone release, sodium retention, and cardiac and renal remodeling [1,3]. Pharmacological blockade of this activity with angiotensin receptor blockers (ARBs) is a cornerstone of therapy for hypertension, chronic kidney disease, and heart failure, underscoring its clinical relevance [1,3]. Moreover, the concept of functional selectivity at AGTR1 has revealed that different ligands can stabilize distinct receptor conformations that preferentially activate specific downstream pathways, opening avenues for biased-agonist drug discovery [4,8]. Understanding GO:0001596 at the molecular level is therefore essential for both basic cardiovascular biology and translational medicine [2,7].
• Central mediator of blood pressure and fluid homeostasis through angiotensin II signaling [1,2].
• Therapeutic target of ARBs in hypertension, chronic kidney disease, and heart failure [1,3].
• Exhibits functional selectivity, allowing biased agonism and pathway-specific drug development [4,8].
• Couples to Gq/PLC/Ca2+ and also to Jak2-Stat1/Stat3, linking to inflammation and hypertrophy [7,8].
• Agonist residence time controls tachyphylaxis, affecting receptor responsiveness.
• Counter-regulated by AGTR2 and alternative RAS peptides, which modulate its effects [2,5,6].
• Involved in renal protection and glomerular function, as shown by AGTR2 studies.
• Relevant to inflammation and immune modulation via RAS signaling.
• Subject to molecular determinants that dictate ligand-specific signaling.
• Amenable to CRISPR-based functional dissection in cell models [3,4].
Molecular Mechanism of angiotensin type I receptor activity
Ligand binding and receptor activation
In simple terms: Angiotensin II binds to the AT1 receptor, flipping a switch that turns on the receptor.
Angiotensin II binds to the extracellular domains of AGTR1, a seven-transmembrane G protein-coupled receptor, inducing conformational changes that allow the receptor to act as a guanine nucleotide exchange factor for Gq [2,8]. The binding kinetics, particularly agonist residence time, determine the duration of receptor activation and the development of tachyphylaxis.
Gq-mediated phospholipase C activation
In simple terms: The activated receptor turns on an enzyme that cuts a membrane lipid into two messenger molecules.
Activated AGTR1 couples to Gq, which stimulates phospholipase C to hydrolyze phosphatidylinositol 4,5-bisphosphate into inositol 1,4,5-trisphosphate (IP3) and diacylglycerol (DAG) [1,2]. This is the defining signaling mechanism of GO:0001596.
Calcium signaling and protein kinase C activation
In simple terms: One messenger releases calcium inside the cell, while the other activates a kinase, together changing cell behavior.
IP3 triggers calcium release from intracellular stores, raising cytosolic Ca2+ and activating calcium-dependent processes, while DAG activates protein kinase C [2,8]. These events mediate smooth muscle contraction, aldosterone secretion, and gene expression changes [1,3].
Additional signaling via Jak2-Stat1/Stat3
In simple terms: The receptor can also directly activate a kinase pathway that controls gene transcription.
Beyond Gq, AGTR1 can couple to Jak2 kinase, leading to phosphorylation and activation of Stat1 and Stat3 in cardiac myocytes. This pathway contributes to hypertrophic and inflammatory gene programs and exemplifies the additional signaling mechanisms noted in the GO definition [7,8].
Functional selectivity and biased agonism
In simple terms: Different drugs binding the same receptor can make it signal in different ways.
Molecular determinants within AGTR1 allow different ligands to stabilize distinct active conformations, preferentially activating Gq versus beta-arrestin or Jak2 pathways [4,8]. This functional selectivity is a key concept for understanding GO:0001596 and for designing pathway-selective therapeutics.
Key Genes Involved in GO:0001596 angiotensin type I receptor activity
The following genes and proteins are central to angiotensin type I receptor activity and its regulation.
| Gene | Major Role | Research Relevance |
|---|---|---|
| AGTR1 | Encodes the angiotensin II type 1 receptor, the prototypical protein for GO:0001596 | Primary target for knockout, point-mutation, and knock-in studies of receptor signaling [2,3] |
| AGTR2 | Encodes the angiotensin II type 2 receptor, which counter-regulates AGTR1 | Studied for protective effects in glomerular and cardiovascular biology [5,6] |
| AGT | Encodes angiotensinogen, the precursor of angiotensin peptides | Relevant to ligand availability and RAS activation |
| REN | Encodes renin, the rate-limiting enzyme in angiotensin II production | Target for modulating ligand-dependent activation of AGTR1 [1,2] |
| ACE | Encodes angiotensin-converting enzyme, which generates angiotensin II | Determines local angiotensin II levels and receptor activation [2,3] |
| ACE2 | Encodes angiotensin-converting enzyme 2, which produces alternative RAS peptides | Part of the counter-regulatory RAS arm |
| JAK2 | Kinase that couples to AGTR1 for Stat activation | Studied for non-Gq signaling by AGTR1 |
| STAT1 | Transcription factor activated downstream of AGTR1-Jak2 | Readout of additional signaling mechanisms |
| STAT3 | Transcription factor activated downstream of AGTR1-Jak2 | Linked to hypertrophy and inflammation |
| GNAQ | Encodes Gq alpha subunit | Mediates PLC activation by AGTR1 [1,2] |
| PLCB1 | Phospholipase C beta 1, effector of Gq signaling | Key enzyme in phosphoinositide hydrolysis |
| ARRB1 | Beta-arrestin 1, involved in receptor desensitization and biased signaling | Studied for functional selectivity of AGTR1 |
| ARRB2 | Beta-arrestin 2, involved in receptor internalization and signaling | Modulates AGTR1 trafficking and signaling |
| AGTRAP | AT1 receptor-associated protein, modulates receptor trafficking | Potential regulator of AGTR1 surface expression |
| CYP11B2 | Aldosterone synthase, downstream of AGTR1 in adrenal gland | Physiological readout of AGTR1 activity |
| NOS3 | Endothelial nitric oxide synthase, modulated by AGTR1 signaling | Links AGTR1 to endothelial function |
| TGFB1 | Transforming growth factor beta 1, induced by AGTR1 in fibrosis | Mediator of renal and cardiac remodeling |
| NFKB1 | Nuclear factor kappa B, linked to AGTR1-mediated inflammation | Inflammatory signaling downstream of AGTR1 |
How Is angiotensin type I receptor activity Regulated?
Angiotensin type I receptor activity is regulated at multiple levels. Receptor desensitization and internalization are controlled by beta-arrestins and G protein-coupled receptor kinases, which terminate Gq signaling and initiate alternative signaling cascades. Agonist residence time at the receptor determines the onset of tachyphylaxis, a form of rapid desensitization. The counter-regulatory arm of the renin-angiotensin system, including AGTR2 and alternative peptides such as angiotensin-(1-7), opposes AGTR1-mediated effects [2,5,6]. Additionally, inflammatory mediators and growth factors can modulate AGTR1 expression and signaling, contributing to disease progression. Molecular determinants within the receptor itself dictate functional selectivity, allowing different ligands to activate distinct pathways.
angiotensin type I receptor activity and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| AGTR1 | Hypertension, heart failure | AGTR1 knockout and point-mutation cell models to dissect Gq vs. beta-arrestin signaling [1,4] |
| AGTR2 | Glomerular protection, renal disease | AGTR2 overexpression and knockout in podocytes or mesangial cells [5,6] |
| JAK2 | Cardiac hypertrophy, inflammation | JAK2 knockout or kinase-dead knock-in in cardiomyocytes |
| STAT3 | Hypertrophy, fibrosis | STAT3 knockout and reporter knock-in for transcriptional readouts |
| ACE2 | Counter-regulatory RAS, cardiovascular protection | ACE2 overexpression and knockout models to study angiotensin-(1-7) effects |
Hypertension and cardiovascular disease
AGTR1-mediated signaling is a major driver of vasoconstriction and sodium retention, and its overactivity contributes to hypertension and heart failure [1,3]. Angiotensin receptor blockers (ARBs) that target this activity are standard therapies for these conditions. Studies of agonist residence time and tachyphylaxis have provided insights into how receptor kinetics influence blood pressure control.
Chronic kidney disease
Renin-angiotensin system inhibition, including blockade of AGTR1, slows the progression of chronic kidney disease. The protective role of AGTR2 in the glomerulus has been investigated as a counter-regulatory mechanism that may be exploited therapeutically. AGTR1-driven fibrosis and inflammation contribute to renal injury.
Inflammation and immune modulation
AGTR1 signaling activates pro-inflammatory pathways, including NF-kB and Jak2-Stat, linking the renin-angiotensin system to chronic inflammation [3,7]. This has implications for diseases beyond the cardiovascular system, including metabolic and autoimmune conditions.
Cardiac hypertrophy and remodeling
AGTR1 couples to Jak2-Stat1/Stat3 in cardiac myocytes, promoting hypertrophic gene expression and remodeling. Functional selectivity at AGTR1 may determine whether signaling leads to adaptive or maladaptive cardiac responses.
From angiotensin type I receptor activity-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does AGTR1 mediate Gq-dependent calcium signaling? | AGTR1 knockout cells with calcium imaging and PLC assays [1,2] |
| How does agonist residence time affect tachyphylaxis? | AGTR1 point mutants with altered ligand binding kinetics |
| What is the role of Jak2-Stat signaling downstream of AGTR1? | JAK2 knockout or STAT1/STAT3 knockout cells |
| Can biased agonism be engineered at AGTR1? | AGTR1 knock-in mutations that disrupt specific signaling arms |
| How does AGTR2 counter-regulate AGTR1? | AGTR2 overexpression in AGTR1-expressing cells [5,6] |
| What is the impact of AGTR1 on inflammatory gene expression? | AGTR1 knockout macrophages or endothelial cells with RNA-seq |
How to Study the angiotensin type I receptor activity Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Calcium imaging | Intracellular Ca2+ mobilization | Assessing Gq-PLC signaling downstream of AGTR1 [1,2] |
| IP3 assay | Phosphoinositide hydrolysis | Confirming PLC activation by AGTR1 |
| RNA-seq | Transcriptional changes | Identifying AGTR1-dependent gene programs [3,7] |
| Phosphoproteomics | Phosphorylation events | Mapping Jak2-Stat and other signaling nodes |
| Radioligand binding | Agonist affinity and residence time | Studying tachyphylaxis and biased agonism [4,8] |
| Beta-arrestin recruitment assay | Functional selectivity | Distinguishing Gq vs. beta-arrestin signaling |
| CRISPR knockout screening | Gene essentiality and modifiers | Identifying regulators of AGTR1 signaling |
| Immunofluorescence | Receptor localization and internalization | Studying AGTR1 trafficking |
Calcium imaging and phosphoinositide hydrolysis assays
Calcium imaging using fluorescent dyes or genetically encoded indicators measures the Ca2+ mobilization that follows Gq-mediated PLC activation, a defining feature of GO:0001596 [1,2]. Phosphoinositide hydrolysis can be assessed by measuring IP3 production or using PLC activity reporters.
Transcriptomics and pathway analysis
RNA-seq of cells with AGTR1 knockout or point mutations can reveal downstream transcriptional programs, including Stat1/Stat3 targets and inflammatory genes [3,7]. Pathway enrichment analysis helps link GO:0001596 to broader biological processes.
Proteomics and phosphoproteomics
Mass spectrometry-based phosphoproteomics can identify signaling nodes activated by AGTR1, such as Jak2 and Stat phosphorylation events. This approach is useful for mapping the additional signaling mechanisms noted in the GO definition [7,8].
Receptor binding and kinetic assays
Radioligand binding and kinetic assays measure agonist affinity and residence time at AGTR1, which are critical for understanding tachyphylaxis and functional selectivity [4,8]. These methods help characterize point mutations that alter receptor pharmacology.
How CRISPR Can Be Used to Study GO:0001596 angiotensin type I receptor activity
Knockout
CRISPR knockout of AGTR1 or its downstream effectors (e.g., GNAQ, PLCB1, JAK2) can abolish specific signaling arms and reveal their contribution to GO:0001596 [1,2,7]. Knockout cell models are valuable for validating drug targets and for phenotypic screens.
Point Mutation
Point mutations in AGTR1 can be introduced to disrupt ligand binding, G protein coupling, or phosphorylation sites, allowing precise dissection of receptor function [4,8]. Such models are essential for studying functional selectivity and tachyphylaxis.
Knock-in
Knock-in of tagged or reporter versions of AGTR1 enables real-time tracking of receptor localization, trafficking, and signaling in live cells. Knock-in of disease-associated variants can model human phenotypes.
Overexpression
Overexpression of AGTR1 or AGTR2 in cell lines can amplify signaling for biochemical assays and mimic pathological overactivation [5,6]. This approach is useful for studying counter-regulatory mechanisms and for drug screening.
How EDITGENE Supports angiotensin type I receptor activity Research
Researchers studying angiotensin type I receptor activity-related genes often need to determine whether a candidate gene is causally involved in receptor signaling, whether a specific mutation alters receptor function, or whether a pathway can be modulated therapeutically. EDITGENE provides a comprehensive suite of CRISPR-based services to address these questions with precision and reproducibility.
Contact EDITGENE today to design your custom CRISPR model for angiotensin type I receptor activity research.
Frequently Asked Questions About angiotensin type I receptor activity
What is angiotensin type I receptor activity?
Angiotensin type I receptor activity (GO:0001596) is a molecular function defined as an angiotensin receptor activity that acts via Gq-mediated activation of phospholipase C followed by phosphoinositide hydrolysis and Ca2+ signaling, and may act via additional signaling mechanisms [1,2].
What genes are involved in angiotensin type I receptor activity?
The primary gene is AGTR1, which encodes the angiotensin II type 1 receptor. Other involved genes include AGTR2, JAK2, STAT1, STAT3, GNAQ, and PLCB1 [2,3,7].
What is the GO ID for angiotensin type I receptor activity?
The GO ID is GO:0001596, under the molecular_function ontology.
How does angiotensin type I receptor signaling work?
Angiotensin II binds AGTR1, which activates Gq, stimulating phospholipase C to hydrolyze phosphoinositides into IP3 and DAG, leading to calcium release and protein kinase C activation [1,2].
What diseases are associated with angiotensin type I receptor activity?
It is associated with hypertension, chronic kidney disease, heart failure, cardiac hypertrophy, and inflammation [1,3,7].
What is the synonym for GO:0001596?
The synonym is PLC-activating angiotensin receptor activity.
How can CRISPR be used to study angiotensin type I receptor activity?
CRISPR knockout, point mutation, knock-in, and overexpression models allow precise dissection of AGTR1 signaling, including Gq-dependent and Jak2-Stat pathways [3,4,7].
What is functional selectivity at the angiotensin II type 1 receptor?
Functional selectivity, or biased agonism, refers to the ability of different ligands to stabilize distinct receptor conformations that preferentially activate specific signaling pathways [4,8].
What is tachyphylaxis in the context of AGTR1?
Tachyphylaxis is a rapid desensitization of the receptor that is defined by agonist residence time at AGTR1.
What research methods are used to study angiotensin type I receptor activity?
Common methods include calcium imaging, IP3 assays, RNA-seq, phosphoproteomics, radioligand binding, and beta-arrestin recruitment assays [1,2,4,7,8].
Conclusion
Angiotensin type I receptor activity (GO:0001596) is a fundamental molecular function that mediates the diverse actions of angiotensin II through Gq-mediated phospholipase C activation and additional signaling pathways such as Jak2-Stat [1,2,7]. Its central role in cardiovascular and renal physiology, combined with its clinical importance as a drug target, makes it a focal point for both basic and translational research [1,3]. Advances in CRISPR-based cell modeling now enable precise interrogation of AGTR1 signaling, functional selectivity, and its counter-regulation by AGTR2 and alternative RAS components [4,5,6,8]. Continued research into GO:0001596 promises to uncover new therapeutic strategies for hypertension, kidney disease, and inflammation [3,5].
References
- 1. Bhandari S et al.. 2022. Renin-Angiotensin System Inhibition in Advanced Chronic Kidney Disease.. N Engl J Med 387(22):2021-2032 PMID: 36326117
- 2. Bader M et al.. 2024. Alternative Renin-Angiotensin System.. Hypertension 81(5):964-976 PMID: 38362781
- 3. Cantero-Navarro E et al.. 2021. Renin-angiotensin system and inflammation update.. Mol Cell Endocrinol 529:111254 PMID: 33798633
- 4. Duarte DA et al.. 2022. Angiotensin II Type 1 Receptor Tachyphylaxis Is Defined by Agonist Residence Time.. Hypertension 79(1):115-125 PMID: 34739768
- 5. Patel S et al.. 2022. Protecting glomerulus: role of angiotensin-II type 2 receptor.. Clin Sci (Lond) 136(20):1467-1470 PMID: 36287192
- 6. Hansen JL et al.. 2000. Functional reconstitution of the angiotensin II type 2 receptor and G(i) activation.. Circ Res 87(9):753-9 PMID: 11055978
- 7. McWhinney CD et al.. 1997. The type I angiotensin II receptor couples to Stat1 and Stat3 activation through Jak2 kinase in neonatal rat cardiac myocytes.. J Mol Cell Cardiol 29(9):2513-24 PMID: 9299374
- 8. Aplin M et al.. 2009. Molecular determinants of angiotensin II type 1 receptor functional selectivity.. J Mol Cell Cardiol 46(1):15-24 PMID: 18848837
